LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Alkermes PLC

Fechado

SetorSaúde

27.86 -1.94

Visão Geral

Variação de preço das ações

24h

Atual

Mín

27.61

Máximo

28.48

Indicadores-chave

By Trading Economics

Rendimento

65M

87M

Vendas

84M

391M

P/E

Médio do Setor

13.995

35.733

EPS

0.291

Margem de lucro

22.295

Funcionários

1,800

EBITDA

99M

113M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+34.67% upside

Dividendos

By Dow Jones

Próximos Ganhos

23 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

470M

4.8B

Abertura anterior

29.8

Fecho anterior

27.86

Sentimento de Notícias

By Acuity

50%

50%

173 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Alkermes PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de set. de 2025, 23:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 de set. de 2025, 22:02 UTC

Grandes Movimentos do Mercado

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 de set. de 2025, 17:01 UTC

Grandes Movimentos do Mercado

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 de set. de 2025, 17:01 UTC

Grandes Movimentos do Mercado

Tron Shares Rise After New Investment From Bravemorning

8 de set. de 2025, 16:14 UTC

Grandes Movimentos do Mercado

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 de set. de 2025, 16:13 UTC

Grandes Movimentos do Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 de set. de 2025, 22:56 UTC

Conversa de Mercado

Worst May Be Over for New Zealand Retailers -- Market Talk

8 de set. de 2025, 22:23 UTC

Conversa de Mercado

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 de set. de 2025, 21:51 UTC

Conversa de Mercado

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 de set. de 2025, 21:47 UTC

Grandes Movimentos do Mercado

Microsoft Signs $17.4B AI Deal With Nebius

8 de set. de 2025, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 de set. de 2025, 21:20 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 de set. de 2025, 21:19 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 de set. de 2025, 21:18 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 de set. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

8 de set. de 2025, 19:33 UTC

Conversa de Mercado

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 de set. de 2025, 19:22 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 de set. de 2025, 19:02 UTC

Conversa de Mercado

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 de set. de 2025, 18:24 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de set. de 2025, 18:24 UTC

Conversa de Mercado

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 de set. de 2025, 17:29 UTC

Conversa de Mercado

Mexican Inflation Seen Little Changed in August -- Market Talk

8 de set. de 2025, 16:59 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 de set. de 2025, 16:36 UTC

Conversa de Mercado

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 de set. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de set. de 2025, 16:16 UTC

Ganhos

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 de set. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de set. de 2025, 16:04 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Alkermes PLC Previsão

Preço-alvo

By TipRanks

34.67% parte superior

Previsão para 12 meses

Média 40.32 USD  34.67%

Máximo 54 USD

Mínimo 26.13 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Alkermes PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

14 ratings

9

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

27.95 / 30.91Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Strong Bullish Evidence

Sentimento

By Acuity

173 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat